The Competition and Markets Authority (CMA) issued proceedings in the High Court of Justice, Business and Property Courts seeking the disqualification of Mr Pritesh Sonpal, a director of Lexon (UK).
The proceedings arise from the CMA’s decision dated 4 March 4, 2020, that between 2015 and 2017, Lexon, King Pharmaceuticals Limited, and Alissa Healthcare Research exchanged commercially sensitive information about prices for Nortriptyline Tablets, the volumes they were supplying, and Alissa’s plans to enter the market.
The CMA found that Lexon participated in the infringing behavior during the period from July 27, 2015, to May 27, 2016. Lexon have filed an appeal in the Competition Appeal Tribunal against CMA’s decision and the penalty imposed.
